1.5900
07-二月-25 15:45:00
15 分钟延时
股票
-0.0300
-1.85%
今日范围
1.5500 - 1.6200
ISIN
N/A
来源
NASDAQ
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
18 9月 2024 07:30:00 条件 Nasdaq GlobeNewswire